Adherium's partnership with US Intermountain Health and CareCentra

Adherium Limited (ASX: $ADR) has enrolled the first patient in a significant research partnership with US Intermountain Health and CareCentra. The partnership aims to examine the benefit of embedding e-health systems to improve patient outcomes and lower health care costs using Hailie® sensors to monitor key physiological data.

Executive commentary on the partnership and study

Adherium CEO, Dr. Paul Mastoridis, expressed excitement about the groundbreaking partnership, highlighting the potential clinical validation of Hailie's next generation sensors and the measurement of behavioral shifts and healthcare cost reductions. Intermountain Health Associate Medical Director, Peter Crossno, M.D., Ph.D., emphasized the potential of the iCare model to provide immediate feedback and trends to patients and their carers on adherence, inhaler technique, triggers, and more.

Summary of the e-health respiratory management study

Adherium's partnership with US Intermountain Health and CareCentra aims to conduct a large-scale real-world chronic respiratory disease clinical study using Hailie® sensors. The study will involve 2,500 patients across five Intermountain facilities over two years to transform respiratory management for chronic obstructive pulmonary disease (COPD) and asthma patients. The study's goal is to leverage cutting-edge digital health technology and respiratory biomarkers to identify rising risks, engage patients and providers in co-managing that risk, and reduce healthcare costs.